^
Association details:
| Biomarker: | CDKN2A overexpression |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Differential expression of DNA damage response and repair genes as a predictive biomarker of response to trabectedin and PARP1 inhibitor in advanced soft tissue sarcomas
Published date:
05/28/2021
Excerpt:
Analyses were done on basal (i.e.:before treatment) diagnostic or surgical sarcoma specimens obtained from patients treated with TR+OL and who did reach a 6-month progression-free survival (responder) or did not (non-responders)....the expression of CDKN2A, PI3KR1, SLFN11, ATM significantly higher in responders than in non-responder patients while APEX2, BLM, RAD54L, XRCC2, MAD2L2 was lower.
Secondary therapy:
trabectedin
